NASDAQ:SYBX

Synlogic Q3 2025 Earnings Results & Report

Synlogic logo
$0.98 0.00 (0.00%)
As of 11/18/2026 11:03 AM Eastern

Synlogic missed analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.19 versus the -$0.11 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
4:00 PM ET

Synlogic EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.11
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Synlogic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Synlogic Q3 2025 Earnings FAQ

Synlogic (NASDAQ:SYBX) reported earnings of -$0.19 per share for Q3 2025, missing the consensus estimate of -$0.11. The report was announced on Thursday, November 13, 2025.

Synlogic Earnings Headlines

Synlogic (SYBX) Set to Post Earnings on Wednesday
A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Synlogic Challenges Nasdaq Delisting Notice
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX) is a biotechnology company that has focused on developing “synthetic biotics”—engineered bacteria designed to perform therapeutic functions in the body. Its approach uses synthetic biology to modify microbes so they can produce or consume specific substances, with the aim of treating disease.

The company’s research has centered on rare metabolic disorders, including phenylketonuria (PKU) and homocystinuria. Its investigational programs were designed to help break down compounds that build up in people with these conditions. Synlogic has not been known for marketed medicines; its work has been primarily in research and clinical development.

Founded in 2013 as a spinout from the Massachusetts Institute of Technology, Synlogic has been based in Cambridge, Massachusetts. Its programs and platform have been directed mainly toward the development of treatments for patients with metabolic diseases.

View Synlogic Profile